Determination of immune response checkpoints in cancer patients receiving immune therapy

Mochalova Anastasiia Sergeevna

Objective. Determination of immune checkpoints and evaluation of the effectiveness of the use of immune checkpoint inhibitors in the treatment of patients with melanoma. Materials and methods of work. A study of 50 patients (mean age 64.82 ± 3.24 years) with melanoma of various localization and who received systemic therapy (including surgical treatment) was accepted in the work: 21 men (mean age 62.92 ± 3.15 years) and 29 women (mean age 66.17 ± 3.31). From the moment of inclusion in the study, the subjects received immunotherapy - a PD-1 blocker: nivolumab / pembrolizumab. No clinically significant side effects were observed against the background of treatment, the therapy was tolerated satisfactorily. Checkpoint immune points (PD-1, PDL-1, B7-H3, sHLA, CD314-1, sULPB) were determined three times. To structure and process statistical data, we used Microsoft Excel from the Microsoft Office software package and the STATISTICA software package for statistical analysis. The results were evaluated as M ± m, the differences were considered significant at p <0.05. Results. Significantly (p <0.05) frequent registration of a complete response was registered among women in the study group; stabilization of the state was more often observed in men (66.67% and 58.62%, respectively). There was a marked downward trend in the control points: PD-1 and B7-H3, an increase in CD314-1, sHLA. Conclusion. Further studies studying the features of antitumor therapy for melanoma with the use of PD-1 blockers will optimize the therapeutic tactics of managing patients in this cohort, as well as improve the prognosis of the course of the disease and life.

Keywords:checkpoints, melanoma, immunotherapy, PD-1, PDF-1.